Upexi, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US39959A1060
USD
1.09
-10.9 (-90.91%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Chromadex Corp.
Nature's Sunshine Products, Inc.
LifeVantage Corp.
Upexi, Inc.
Natural Alternatives International, Inc.
ProPhase Labs, Inc.
USANA Health Sciences, Inc.
Revolution Medicines, Inc.
Cidara Therapeutics, Inc.
MIRA Pharmaceuticals, Inc.
Bright Green Corp.

Why is Upexi, Inc. ?

1
Poor Management Efficiency with a low ROCE of 2.46%
  • The company has been able to generate a Return on Capital Employed (avg) of 2.46% signifying low profitability per unit of total capital (equity and debt)
2
Flat results in Mar 25
3
Below par performance in long term as well as near term
  • Along with generating -53.42% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Upexi, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Upexi, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Upexi, Inc.
-100.0%
-0.22
367.17%
S&P 500
13.99%
0.81
19.85%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
24.53%
EBIT Growth (5y)
-217.23%
EBIT to Interest (avg)
-2.44
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
3.90
Sales to Capital Employed (avg)
1.92
Tax Ratio
11.97%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
11.84%
ROCE (avg)
2.46%
ROE (avg)
2.47%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
229.66
EV to EBIT
-38.26
EV to EBITDA
-44.95
EV to Capital Employed
47.70
EV to Sales
25.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-124.67%
ROE (Latest)
-616.52%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -765.14% (YoY

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS

Here's what is working for Upexi, Inc.

Raw Material Cost
Fallen by -765.14% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales